Pravastatin for severe preeclampsia with growth restriction: Placental findings and infant follow-up

• Published in: European journal of obstetrics & gynecology and reproductive biology 2023-04, Vol.283, p.37-42
• Main Authors: Fruci, Stefano, Salvi, Silvia, Moresi, Sascia, Gallini, Francesca, Dell'Aquila, Marco, Arena, Vincenzo, Di Stasio, Enrico, Ferrazzani, Sergio, De Carolis, Sara, Lanzone, Antonio
• Format: Article
• Language: English
• Subjects: Female; Fetal Growth Retardation - drug therapy; Follow-Up Studies; Humans; Infant; Infant, Newborn; Intrauterine growth restriction; Placenta; Pravastatin; Pravastatin - therapeutic use; Pre-Eclampsia - drug therapy; Pre-Eclampsia - prevention & control; Preeclampsia; Pregnancy; Pregnancy Outcome; Preterm delivery
• ISSN: 0301-2115; 1872-7654
• DOI: 10.1016/j.ejogrb.2023.01.036

•Preeclampsia is the leading cause of premature delivery worldwide.•Pravastatin given in the second trimester may increase the duration of early severe preeclampsia.•Our data suggest a role of pravastatin in stabilizing the progression of preeclampsia.•No differences in infant follow-up are observed between treated and not-treated pregnancies. Preeclampsia (PE) is the major cause of maternal morbidity and mortality and the leading cause of premature delivery worldwide. As well as intrauterine growth restriction (IUGR), PE is associated with pathogenic evidence of placental malperfusion and ischemia. Recent literature has highlighted the potential of pravastatin in the prevention and treatment of these conditions. Aim of this study is to describe perinatal outcomes and placental histopathological findings in a small series of pregnant women with severe PE and IUGR treated with pravastatin on compassionate grounds. Two-year follow up of these babies is provided. Between October 2017 and October 2019 in Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy, women with singleton pregnancy between 19.6 and 27.6 gestational weeks, who presented with severe PE and IUGR were counselled for a compassionate treatment with Pravastatin 40 mg a day. Treated women were compared with controls identified with similar data in terms of gestational age at diagnosis, clinical maternal data, Doppler severity findings. Neonates were followed up for two years. The median time from diagnosis to delivery was 39 days (IQR 20) for women in the pravastatin group and 20 days (IQR 20.5) for controls. Looking to maternal blood exams, in the group of women treated with pravastatin, maximum transaminase, creatinine levels were lower than in controls, where the minimum platelet count was higher. Placenta examination did not reveal any significant differences in placental histopathological findings. No significant differences were observed in the investigated perinatal data, as well as in infant follow-up, although an increased prenatal weight gain was found in treated pregnancies in comparison to controls. Our data did not allow us to find significant differences in pregnancy outcome and infant follow-up, as well as in placental histological picture in preeclamptic patients when pravastatin is administered in the late second trimester. However, we suggest its possible role in stabilizing the disease, increasing the prenatal weight gain and prolonging the duration of pre